BIIB Stock Summary and Trading Ideas (Biogen | NASDAQ:BIIB)

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

What symbol and exchange does Biogen shares trade?

Biogen trades on the NASDAQ stock market under the symbol BIIB.

What is Biogen stock price doing today?

As of January 16, 2026, BIIB stock price declined to $164.42 with 1,658,718 million shares trading.

What is Biogen's Beta?

BIIB has a beta of 0.67, meaning it tends to be less sensitive to market movements. BIIB has a correlation of 0.11 to the broad based SPY ETF.

How much is Biogen worth?

BIIB has a market cap of $24.12 billion. This is considered a Large Cap stock.

How much money does Biogen make?

Last quarter Biogen reported $3 billion in Revenue and $4.81 earnings per share. This beat revenue expectation by $192 million and exceeded earnings estimates by $.92.

What is the highest and lowest price Biogen traded in the last 3 year period?

In the last 3 years, BIIB traded as high as $319.76 and as low as $110.04.

What are the top ETFs holding Biogen?

The top ETF exchange traded funds that BIIB belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.

Is Biogen (BIIB) a good investment?

BIIB has underperformed the market in the last year with a price return of +16.6% while the SPY ETF gained +17.9%. However, in the short term, BIIB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +14.5% vs +4.3% return in SPY. But in the last 2 weeks, BIIB shares have been beat by the market, returning -6.6% compared to an SPY return of +1.4%.

What are the support and resistance levels for Biogen (BIIB)?

BIIB support price is $165.07 and resistance is $172.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIIB shares will trade within this expected range on the day.